Loading
The 1935 report in which Allen Whipple and two colleagues described removing the head of the pancreas and the duodenum for cancer at the junction of the bile duct and bowel, the operation that still carries his name and remains the only route to cure.
Whipple, Parsons and Mullins, Annals of Surgery, October 1935, pages 763 to 779. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the paper is the origin of the two-stage, then one-stage, pancreaticoduodenectomy. Nine decades later the operation, refined by Traverso and Longmire's pylorus-preserving variant (1978) and by centralisation into high-volume centres, is still the only treatment that cures pancreatic cancer, and about one patient in five presents with disease that can be removed.
Every treatment on this roadmap is either a way to reach this operation, a way to make it work better, or a substitute for patients who cannot have it.
Shares Preservation of the pylorus in pancreaticoduodenectomy, Whipple procedure (pancreaticoduodenectomy), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Preservation of the pylorus in pancreaticoduodenectomy, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Resectable, borderline resectable and unresectable, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Resectable pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Resectable, borderline resectable and unresectable, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.